{
  "docId": "019de514-b808-755e-8f46-3355c3a68f91",
  "docSlug": "726904051bada761abf371aad4bc9c4e",
  "documentTitle": "Avantor | Investor Conference Presentation Deck | 26 slides",
  "authorId": "avantor",
  "authorName": "Avantor",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "frame_situation",
  "density": "dense",
  "nDataPoints": 20,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-b808-755e-8f46-3355c3a68f91/11",
  "deckHref": "/decks/019de514-b808-755e-8f46-3355c3a68f91",
  "deckJsonHref": "/decks/019de514-b808-755e-8f46-3355c3a68f91.json",
  "deckAnchorHref": "/decks/019de514-b808-755e-8f46-3355c3a68f91#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.57,
        "w": 0.34,
        "x": 0.32,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Est. worldwide biopharma drug revenue², USD, Bn; mAbs: 2020: 256, 2025: 414, 10% CAGR; Cell Therapy & Viral Vector: 2020: 2, 2025: 32, 69% CAGR; DNA/RNA: 2020: 3, 2025: 19, 42% CAGR; Other: 2020: 35, 2025: 62, 12% CAGR",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3412fe1-39c3-4132-8ce4-5f66e67b4a05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.57,
        "w": 0.31,
        "x": 0.66,
        "y": 0.32
      },
      "kind": "chart",
      "text": "FDA new molecular entity approvals³; 2012-16: 310 total (136 Biologics License Applications, 174 New Drug Applications); 2017-21: 442 total (190 Biologics License Applications, 252 New Drug Applications)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "758db494-b44b-4a38-a9b6-d7f1d5710ccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.57,
        "w": 0.29,
        "x": 0.03,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Total worldwide venture funding raised by biotech companies¹, USD, Bn; 2017: 19.4; 2021: 39.2; +19%",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cc62be1-b954-41b8-a0a2-8d623f2c3116",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.6,
        "x": 0.19,
        "y": 0.91
      },
      "kind": "list",
      "text": "1. BCIQ (Oct 2021) with updated figures for 2021 as of 12/29/21. Includes seed funding, series A-E and higher, debt, non-disclosed, general venture funding.\n2. Includes traditional mAbs, recombinants and other protein-based therapeutics; Evaluate Pharma (Dec. 2021)\n3. FDA, Nephron Research as of 11/30/21",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9487f0bb-04b8-4bc1-948b-6f3834ac464e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.69,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Avantor growth fueled by strong biopharma industry fundamentals...",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6529ea73-d6ab-431b-a30b-abed490e8d4f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "267820d8-3011-4530-b4df-284db2c12563",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The deck presents various financial metrics, including top-line and bottom-line growth, and 2022 full-year guidance.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 11,
      "name": "Tale Two Worlds",
      "slug": "04-tale-two-worlds",
      "bestFor": "Competitive analysis, benchmarking, case for change",
      "matchId": "7c62ffd9-b2c8-402a-a239-6b6da5e65a56",
      "evidence": "The deck presents a comparison between Avantor's current situation and its future growth prospects.",
      "position": 0,
      "objective": "To contrast Avantor's current situation with its future prospects",
      "structure": "Current State -> Desired State / Benchmark -> The Gap & Implication",
      "confidence": 0.6,
      "description": "Show the gap between two states to drive urgency or highlight opportunity"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}